tetano
Editor, Senior Moderator
J Thorac Oncol
. 2023 Jun 28;S1556-0864(23)00634-2.
doi: 10.1016/j.jtho.2023.06.015. Online ahead of print. Impaired seroconversion after SARS-CoV-2 mRNA vaccine in patients with thymic epithelial tumors
Erica Pietroluongo[SUP] 1 [/SUP], Pietro De Placido[SUP] 1 [/SUP], Marianna Tortora[SUP] 2 [/SUP], Claudia Martinelli[SUP] 1 [/SUP], Angela Viggiano[SUP] 1 [/SUP], Maria Rosaria Saponaro[SUP] 1 [/SUP], Aldo Caltavituro[SUP] 1 [/SUP], Roberto Buonaiuto[SUP] 1 [/SUP], Rocco Morra[SUP] 1 [/SUP], Margaret Ottaviano[SUP] 3 [/SUP], Vitantonio Del Deo[SUP] 2 [/SUP], Gustavo Cernera[SUP] 4 [/SUP], Monica Gelzo[SUP] 4 [/SUP], Anna Maria Malfitano[SUP] 5 [/SUP], Michele Francesco Di Tolla[SUP] 5 [/SUP], Carmine De Angelis[SUP] 1 [/SUP], Grazia Arpino[SUP] 1 [/SUP], Daniela Terracciano[SUP] 5 [/SUP], Roberto Bianco[SUP] 1 [/SUP], Bianca Maria Veneziani[SUP] 6 [/SUP], Pietro Formisano[SUP] 5 [/SUP], Giuseppe Castaldo[SUP] 4 [/SUP], Giovannella Palmieri[SUP] 7 [/SUP], Sabino De Placido[SUP] 8 [/SUP], Mario Giuliano[SUP] 8 [/SUP]
Affiliations
Introduction: Thymic epithelial tumors (TETs) are rare malignancies associated with dysregulation of the immune system and humoral and cell mediated immunity abnormalities. Severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) mRNA vaccine is effective in preventing COVID-19 morbidity and mortality. The aim of this study was to evaluate the seroconversion in TET patients after two doses of mRNA vaccine.
Methods: This is a prospective study where consecutive TET patients were enrolled before receiving the first dose of SARS-CoV-2 mRNA vaccine (BNT162b2 by Pfizer-BioNTech). SARS-CoV-2 spike-binding IgG antibody (Ab) serological levels were analyzed at different time-points, including before first vaccine dose (T0), 1 month after 2[SUP]nd[/SUP] dose (T2) and 3 months after 2[SUP]nd[/SUP] dose (T3).
Results: Overall, 39 patients were included in the analysis. All patients had negative Ab titers at T0. Nineteen (48.7%) patients were in follow-up with no residual tumor lesion/s [referred as no evidence of disease (NED)], and 20 (51.3%) had evidence of disease (ED) and were receiving systemic treatment. Dysregulations of the immune system were diagnosed in 29 patients (74.4%) with Good's Syndrome (GS) being the most frequent immune disorder (48.7 %). At univariate analysis lack of seroconversion at T2 was significantly associated with ED (p<0.001) and with GS (p= 0.043). A significant association with impaired seroconversion was confirmed at multivariate analysis for ED p=0.00101 but not for GS (p= 0.625).
Conclusions: Our data showed that TET patients with ED had substantially higher probability of impaired seroconversion after SARS-CoV-2 mRNA vaccine as compared with NED patients.
Keywords: COVID-19; SARS-CoV-2; autoimmunity; seroconversion; thymic epithelial tumors; vaccine.
. 2023 Jun 28;S1556-0864(23)00634-2.
doi: 10.1016/j.jtho.2023.06.015. Online ahead of print. Impaired seroconversion after SARS-CoV-2 mRNA vaccine in patients with thymic epithelial tumors
Erica Pietroluongo[SUP] 1 [/SUP], Pietro De Placido[SUP] 1 [/SUP], Marianna Tortora[SUP] 2 [/SUP], Claudia Martinelli[SUP] 1 [/SUP], Angela Viggiano[SUP] 1 [/SUP], Maria Rosaria Saponaro[SUP] 1 [/SUP], Aldo Caltavituro[SUP] 1 [/SUP], Roberto Buonaiuto[SUP] 1 [/SUP], Rocco Morra[SUP] 1 [/SUP], Margaret Ottaviano[SUP] 3 [/SUP], Vitantonio Del Deo[SUP] 2 [/SUP], Gustavo Cernera[SUP] 4 [/SUP], Monica Gelzo[SUP] 4 [/SUP], Anna Maria Malfitano[SUP] 5 [/SUP], Michele Francesco Di Tolla[SUP] 5 [/SUP], Carmine De Angelis[SUP] 1 [/SUP], Grazia Arpino[SUP] 1 [/SUP], Daniela Terracciano[SUP] 5 [/SUP], Roberto Bianco[SUP] 1 [/SUP], Bianca Maria Veneziani[SUP] 6 [/SUP], Pietro Formisano[SUP] 5 [/SUP], Giuseppe Castaldo[SUP] 4 [/SUP], Giovannella Palmieri[SUP] 7 [/SUP], Sabino De Placido[SUP] 8 [/SUP], Mario Giuliano[SUP] 8 [/SUP]
Affiliations
- PMID: 37390981
- DOI: 10.1016/j.jtho.2023.06.015
Introduction: Thymic epithelial tumors (TETs) are rare malignancies associated with dysregulation of the immune system and humoral and cell mediated immunity abnormalities. Severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) mRNA vaccine is effective in preventing COVID-19 morbidity and mortality. The aim of this study was to evaluate the seroconversion in TET patients after two doses of mRNA vaccine.
Methods: This is a prospective study where consecutive TET patients were enrolled before receiving the first dose of SARS-CoV-2 mRNA vaccine (BNT162b2 by Pfizer-BioNTech). SARS-CoV-2 spike-binding IgG antibody (Ab) serological levels were analyzed at different time-points, including before first vaccine dose (T0), 1 month after 2[SUP]nd[/SUP] dose (T2) and 3 months after 2[SUP]nd[/SUP] dose (T3).
Results: Overall, 39 patients were included in the analysis. All patients had negative Ab titers at T0. Nineteen (48.7%) patients were in follow-up with no residual tumor lesion/s [referred as no evidence of disease (NED)], and 20 (51.3%) had evidence of disease (ED) and were receiving systemic treatment. Dysregulations of the immune system were diagnosed in 29 patients (74.4%) with Good's Syndrome (GS) being the most frequent immune disorder (48.7 %). At univariate analysis lack of seroconversion at T2 was significantly associated with ED (p<0.001) and with GS (p= 0.043). A significant association with impaired seroconversion was confirmed at multivariate analysis for ED p=0.00101 but not for GS (p= 0.625).
Conclusions: Our data showed that TET patients with ED had substantially higher probability of impaired seroconversion after SARS-CoV-2 mRNA vaccine as compared with NED patients.
Keywords: COVID-19; SARS-CoV-2; autoimmunity; seroconversion; thymic epithelial tumors; vaccine.